Atezolizumab (TECENTRIQ®), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (checkpoint inhibitor), was approved as the first breast cancer immunotherapy to be combined with chemotherapy (Abraxane; nab®-Paclitaxel) for PD-L1-positive TNBC8. Here, CD274 is linked to breast carcinoma.